A single-product company, an entrenched market, and the pull that made it an acquisition target.

The challenge

Patton Surgical Corporation, an Austin-based, venture-backed developer of laparoscopic access devices, built its reputation on the PassPort™ trocar line — engineered to make one of the riskiest moments in minimally invasive surgery, entering the abdominal cavity, measurably safer. The challenge was converting that clinical edge into commercial traction in a market controlled by Covidien, Ethicon Endo-Surgery, and Applied Medical, who dominated U.S. hospital purchasing through bundled contracts and GPO relationships.

As a single-product company competing against multi-billion-dollar device makers, Patton needed enough commercial momentum and durable differentiation to become an attractive acquisition target before its runway ran out.

The Bridge Strategy Blueprint™ implemented

Applying Awareness and Attention, the first two points of the Blueprint, working sessions with Patton’s Founder and CEO revealed the core issue: on a national level, too few laparoscopic surgeons, department directors, and C-suite hospital executives even knew the technology existed, let alone its benefits.

Patton’s prior go-to-market relied on long, capital-equipment-style sales cycles, selling to supply chain and department chairs who evaluated trocars on price and bundling — not the safety data that made PassPort™ clinically distinct. The real buyer was the surgeon who felt the risk every time they entered the abdominal cavity.

Attraction, the third point, identified the shift that mattered most: build demand upstream, in an uncommon way that creates curiosity among surgeons and surgical stakeholders who would pull PassPort™ into their hospital administrators’ field of vision.

The solution

Rather than competing on price and bundling terms Patton could never win alone, the strategy shifted to building a base of multiple surgeon champions across specialties through public relations, publications, live-case demonstrations, and direct engagement with high-volume laparoscopic surgeons.

As more surgeons requested PassPort™ by name, hospital executives grew familiar with it through Patton’s warming of the target market. That pull — not a feature or a lower price — became Patton’s real differentiator, and built exactly the national market traction a strategic acquirer looks for.

Why it worked

When a commercialization strategy is rebuilt around the people who actually feel the product’s value, where it’s used, not just for the purchasing department, it builds more than a sale. It builds the kind of commercial traction that gets abnormally noticed.